MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Naftopidil Is Useful for the Treatment of Malignant Pleural Mesothelioma

Pharmacology 2014 October 4 [Epub ahead of print] [Link]

Mikami K, Nagaya H, Gotoh A, Kanno T, Tsuchiya A, Nakano T, Nishizaki T.

Abstract

Naftopidil, an α1-adrenoceptor blocker, induced apoptosis of human malignant pleural mesothelioma NCI-H2052 cells. Naftopidil upregulated the expression of tumor necrosis factor-α (TNF-α) mRNA in these cells. Naftopidil, alternatively, increased FasL secretion from NCI-H2052 cells, without affecting the expression of FasL mRNA and protein, and activated caspase-3 and -8 in NCI-H2052 cells. Naftopidil drastically suppressed tumor growth in mice inoculated with these cells. The results of the present study indicate that naftopidil induces apoptosis of NCI-H2052 cells by upregulating the expression of TNF-α and stimulating the secretion of FasL, a ligand for the death receptor Fas, both to activate caspase-8 and the effector caspase-3, leading to the suppression of NCI-H2052 cell proliferation in vivo. This raises the possibility that naftopidil could be developed as an effective drug for the treatment of malignant pleural mesothelioma.

Both comments and trackbacks are currently closed.